OpGen is a precision medicine company. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, Co. is developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information about life threatening infections. Co.'s existing product portfolio includes Unyvero, Acuitas Antimicrobial Resistance Gene Panel, and the ARES Technology Platform including ARES reference database on antimicrobial resistance, using next generation sequencing technology and artificial intelligence-powered bioinformatics solutions for antibiotic response prediction, as well as the Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kit. The OPGN stock yearly return is shown above.
The yearly return on the OPGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OPGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|